OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Rule on the Next Steps for BTK Inhibitors in MCL

January 16th 2020

Simon Rule, MD, professor of hematology, University of Plymouth, discusses the next steps for ibrutinib (Imbruvica) and other BTK inhibitors in the treatment landscape of mantle cell lymphoma (MCL).

Dr. Mesa on the Efficacy of Fedratinib in Patients With Myelofibrosis and Low Platelet Counts

January 16th 2020

Ruben A. Mesa, MD, director, The Mays Cancer Center, the newly named center of UT Health San Antonio MD Anderson Cancer Center, discusses the efficacy of fedratinib (Inrebic) in patients with myelofibrosis who have low platelet counts.

Dr. Yardley on the Utility of CDK4/6 Inhibitors in Metastatic HR+ Breast Cancer

January 16th 2020

Denise Yardley, MD, discusses the utility of CDK4/6 inhibitors in hormone receptor

Dr. Schlumbrecht on Remaining Challenges in Uterine Leiomyosarcoma

January 16th 2020

Matthew P. Schlumbrecht, MD, discusses remaining challenges in uterine leiomyosarcoma.

Dr. Hussein on the Evolution of Treatment in HCC

January 16th 2020

Atif Hussein, MD, discusses the evolution treatment in hepatocellular carcinoma.

Dr. Hays on Immunotherapy in Ovarian Cancer Treatment

January 15th 2020

John Hays, MD, PhD, discusses the progression of immunotherapy in treating patients with ovarian cancer.

Dr. Villa on Induction Therapy With Bendamustine/Rituximab in MCL

January 15th 2020

Diego Villa, MD, MPH, discusses a retrospective analysis of bendamustine and rituximab as induction therapy in patients with transplant-eligible and -ineligible mantle cell lymphoma.

Dr. Chittoor on Guidelines for Liquid Biopsies in NSCLC

January 15th 2020

Sreeni Chittoor, MD, FACP, discusses the FDA and National Comprehensive Cancer Network recommendations for use of liquid biopsies in patients with non–small cell lung cancer.

Dr. Mims on Developed Mutations in AML

January 15th 2020

Alice S. Mims, MD, discusses developed resistance in acute myeloid leukemia.

Dr. Graff on Extended Adjuvant Therapy in Early-Stage HR+ Breast Cancer

January 15th 2020

Stephanie L. Graff, MD, discusses the utility of extended adjuvant therapy in women with early-stage hormone receptor-positive, HER2-negative breast cancer.

Dr. Nordquist on Matching Patients to Clinical Trials

January 15th 2020

Luke Nordquist, MD, FACP, discusses matching patients with clinical trials in oncology.

Dr. Rampal on Unmet Needs in Myelofibrosis and Polycythemia Vera

January 15th 2020

Raajit K. Rampal, MD, PhD, discusses unmet needs in the treatment of patients with myelofibrosis and polycythemia vera.

Dr. Woyach on Ongoing Research With BTK Inhibitors in CLL

January 14th 2020

Jennifer Woyach, MD, associate professor, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center–James, discusses ongoing research with BTK inhibitors in chronic lymphocytic leukemia (CLL).

Dr. Martin on Treating First Relapse in Multiple Myeloma

January 14th 2020

Thomas G. Martin, MD, clinical professor of medicine, Adult Leukemia and Bone Marrow Transplantation Program, associate director, Myeloma Program, University of California, San Francisco, and co-leader, Hematopoietic Malignancies Program, Helen Diller Family Comprehensive Cancer Center, discusses the management of first relapse in patients with multiple myeloma.

Dr. Lockhart on Strategies for Targeting the RAS/RAF/MEK/ERK Pathway in CRC

January 14th 2020

A. Craig Lockhart, MD, MHS, professor and associate director for Regional and Strategic Clinical Research Affiliations, Sylvester Comprehensive Cancer Center, University of Miami Health System, discusses investigational strategies targeting the RAS/RAF/MEK/ERK pathway in colorectal cancer (CRC).

Dr. Gerds on Future Treatment of Patients With Myeloproliferative Neoplasms

January 14th 2020

Aaron Gerds, MD, discusses the future treatment of patients with myeloproliferative neoplasms through the use of JAK-STAT pathway.

Addressing Fatigue as an Adverse Event in Ovarian and Uterine Cancers

January 14th 2020

Hanneke Poort, PhD, discusses research regarding fatigue as an adverse event in patients with gynecologic cancer.

Dr. Rohs on the Use Liquid Biopsies in Lung Cancer

January 14th 2020

Nicholas C. Rohs, MD, assistant professor of medicine, hematology, and medical oncology, Icahn School of Medicine, Mount Sinai, discusses the use of liquid biopsies in lung cancer.

Dr. Aoun on Imaging Modalities in Prostate Cancer

January 14th 2020

Hussein Aoun, MD, a radiologist at Barbara Ann Karmanos Cancer Institute, discusses the imaging modalities that are currently being used in prostate cancer and how they compare with conventional imaging modalities.

Dr. Goy on Preliminary Data With Ibrutinib/Venetoclax in Relapsed/Refractory MCL

January 14th 2020

Andre H. Goy, MD, MS, chief, Division of Lymphoma, chairman and director, John Theurer Cancer Center, discusses preliminary data with the combination of ibrutinib (Imbruvica) and venetoclax (Venclexta) in relapsed/refractory mantle cell lymphoma (MCL).